Markets

Former Imprimis Pharmaceuticals subsidiary Eton Pharmaceuticals files for a $21 million IPO

Various market performance charts

Eton Pharmaceuticals, a former subsidiary of Imprimis Pharmaceuticals which is developing multiple candidates for various indications, filed on Friday with the SEC to raise up to $21 million in an initial public offering.

The Deer Park, IL-based company was founded in 2017 and plans to list on the Nasdaq under the symbol ETON. National Securities is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Former Imprimis Pharmaceuticals subsidiary Eton Pharmaceuticals files for a $21 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More